Φιλτράρισμα ανά Last updated date SelectΜετάΠρινFrom - To Date Ημερομηνία λήξης This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate usePRIMECareersMedication errorParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Leave this field blank Filter Αποτελέσματα (3839) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine 11 Νοέμβριος 2022NewsHumanCOVID-19Vaccines Regulatory update - EMA encourages companies to submit type I variations for 2022 by end of November 3 Νοέμβριος 2022NewsCorporateMedicines EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders 3 Νοέμβριος 2022NewsHumanReferrals Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022 28 Οκτώβριος 2022NewsHumanPharmacovigilanceReferrals EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines 28 Οκτώβριος 2022NewsHumanMedicinesReferrals EMA business hours over All Saints' Day and All Souls' Day, 1 and 2 November 28 Οκτώβριος 2022NewsCorporateCOVID-19 EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age 19 Οκτώβριος 2022NewsHumanCOVID-19Vaccines EMA recommends approval of second adapted Spikevax vaccine 19 Οκτώβριος 2022NewsHumanCOVID-19Vaccines Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022 14 Οκτώβριος 2022NewsHumanCOVID-19MedicinesMedicines for use outside the EU First therapy to treat transplant patients with post-transplant lymphoproliferative disease 14 Οκτώβριος 2022NewsHumanMedicines 1 … 38 39 40 41 42 Page 42 of 384 43 44 45 46 … 384
EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine 11 Νοέμβριος 2022NewsHumanCOVID-19Vaccines
Regulatory update - EMA encourages companies to submit type I variations for 2022 by end of November 3 Νοέμβριος 2022NewsCorporateMedicines
EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders 3 Νοέμβριος 2022NewsHumanReferrals
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24 - 27 October 2022 28 Οκτώβριος 2022NewsHumanPharmacovigilanceReferrals
EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines 28 Οκτώβριος 2022NewsHumanMedicinesReferrals
EMA business hours over All Saints' Day and All Souls' Day, 1 and 2 November 28 Οκτώβριος 2022NewsCorporateCOVID-19
EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age 19 Οκτώβριος 2022NewsHumanCOVID-19Vaccines
EMA recommends approval of second adapted Spikevax vaccine 19 Οκτώβριος 2022NewsHumanCOVID-19Vaccines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022 14 Οκτώβριος 2022NewsHumanCOVID-19MedicinesMedicines for use outside the EU
First therapy to treat transplant patients with post-transplant lymphoproliferative disease 14 Οκτώβριος 2022NewsHumanMedicines